Skip to content

Daunorubicin

    Brands

    DEA Class; Rx

    Common Brand Names; Cerubidine

    • Antineoplastics, Anthracycline

    Anthracycline chemotherapy agent
    Used in combination with other anticancer drugs in patients with acute leukemias
    Cardiotoxicity and myelosuppression have been reported

    Indicated for the treatment of acute nonlymphocytic leukemia including acute myelogenous leukemia (AML).

    For the treatment of acute lymphocytic leukemia (ALL).

    Hypersensitivity

    Active infection

    IM or SC administration (vesicant)

    Patients who have received max cumulative dose of daunorubicin or doxorubicin

    Patients with preexisting myelosuppression from other drug treatments

    • Nausea
    • Vomiting
    • Arrhythmias
    • Discoloration of urine
    • Alopecia
    • Injection site skin flare
    • Hyperuricemia
    • GI ulceration
    • Diarrhea
    • Arrhythmia
    • Cardiomyopathy
    • Bilirubin increased
    • Pruritus
    • Urticaria

    Risk of severe cardiotoxicity (including CHF) & myelosuppression

    Caution in hepatic/renal impairment

    Children may be more sensitive to cardiotoxic effects than adults

    Avoid pregnancy

    Secondary leukemias reported when used in combination with radiation or chemotherapy

    Pregnancy Category: D

    Lactation: excretion in milk unknown/not recommended

    Adults

    45 mg/m2 IV, although doses up to 90 mg/m2 IV have been used off-label; maximum cumulative anthracycline dose is 550 mg/m2 (or 400 mg/m2 in patients who have received radiation therapy involving the heart area).

    Geriatric

    45 mg/m2 IV, although doses up to 90 mg/m2 IV have been used off-label; maximum cumulative lifetime anthracycline dose is 550 mg/m2 (or 400 mg/m2 in patients who have received radiation therapy involving the heart area).

    Adolescents

    25 mg/m2 IV weekly; maximum cumulative dose is 300 mg/m2 IV.

    Children

    2 years or older: 25 mg/m2 (or 1 mg/kg in children with a body surface area less than 0.5 m2); maximum cumulative dose is 300 mg/m2 IV.Less than 2 years: 1 mg/kg IV weekly label; maximum cumulative dose is 10 mg/kg.

    Infants

    1 mg/kg IV weekly label; maximum cumulative dose is 10 mg/kg.

    Daunorubicin hydrochloride

    injectable solution

    • 5mg/mL

    powder for injection

    • 20mg